Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study - PubMed
5 hours ago
- #GLP-1
- #Pharmacoepidemiology
- #Diabetes
- The FDA investigated potential risks of suicidal ideation and behaviors associated with GLP-1 receptor agonists (GLP-1 RAs) in type 2 diabetes patients.
- A study compared the risk of intentional self-harm in patients using GLP-1 RAs versus other antidiabetic drugs (SGLT-2is and DPP-4is).
- Data from October 2015 to September 2023 included over 1.1 million new users of GLP-1 RAs, SGLT-2is, and DPP-4is.
- Adjusted incidence rates of intentional self-harm per 1000 person-years were 1.13 for GLP-1 RAs, 1.22 for SGLT-2is, and 1.37 for DPP-4is.
- No increased risk of intentional self-harm was found with GLP-1 RAs compared to SGLT-2is (HR 0.93) or DPP-4is (HR 0.94).
- Subgroup analyses by factors like obesity, psychiatric history, and age showed consistent results.
- The study provides reassurance about the safety of GLP-1 RAs regarding intentional self-harm in type 2 diabetes patients.